No public input from biopharma on emerging tech for export controls

As the comment period for input on how to define emerging technologies under the Export Control Reform Act of 2018 draws to a close

Read the full 249 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE